Navigation Links
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief Financial Officer
Date:8/7/2014

BOTHELL, Wash. and VANCOUVER, British Columbia, Aug. 7, 2014 /PRNewswire/ -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced the appointment of John A. Bencich as Vice President and Chief Financial Officer (CFO).  John Bencich, an experienced life sciences and technology industry executive, is joining the company effective August 11th, 2014. John will lead the company's financial and administrative operations, reporting directly to OncoGenex President and CEO Scott Cormack.

"John brings to our management team proven financial leadership and strategic corporate growth expertise that will be invaluable as we shape the future of OncoGenex," said Scott Cormack, President and CEO of OncoGenex. "The Board of Directors joins me in welcoming John to his new position and we look forward to his substantial contributions to drive OncoGenex' future success."

"The team at OncoGenex is genuinely committed to making a difference in the lives of people suffering from devastating illnesses. I am honored to join in this mission at this exciting time of execution and growth," commented John Bencich.

Prior to his recent appointment at OncoGenex, John served as CFO of Integrated Diagnostics Inc. overseeing finance, corporate development, accounting and human resource functions. Before joining Integrated Diagnostics in 2012, John was CFO of Allozyne, a private, VC-backed company where he led the company's finance, accounting and information technology groups. Earlier he served as the vice president, CFO and treasurer of Trubion Pharmaceuticals, a publicly traded biotechnology company where he helped complete the successful sale of the company to Emergent BioSolutions. Prior to his role at Trubion, he was the director of finance and corporate controller for Onyx Software Corporation, a publicly traded software company. John started his career at Ernst & Young LLP. He graduated from the University of San Diego with a BA in Accounting, earned his MBA from Seattle University and is a Certified Public Accountant.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at www.OncoGenex.com and at the company's Twitter account: https://twitter.com/OncoGenex_IR.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2013 and Addresses Key Questions from Investors on Quarterly Conference Call
2. OncoGenex to Present at Credit Suisse Healthcare Investor Conference
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. OncoGenex Announces Completion Of Patient Enrollment In Custirsen Phase 3 "SYNERGY" Study
5. RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
6. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
7. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
8. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
9. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
10. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
11. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... providing advanced instruments and applications consulting for microscopy and surface analysis, Nanoscience ... application consulting, Nanoscience Analytical offers a broad range of contract analysis services ...
(Date:10/7/2017)... Mass. , Oct. 6, 2017  The ... work of three scientists, Jacques Dubochet, Joachim ... breakthrough developments in cryo-electron microscopy (cryo-EM) ... technology within the structural biology community. The winners ... Scientists can now routinely produce highly resolved, three-dimensional ...
(Date:10/6/2017)... ... 2017 , ... On Tuesday, October 24th, ABC² (Accelerate Brain ... adaptive clinical trial for glioblastoma (GBM). The featured speaker will be Dr. Brian ... to the public, but registration is required. , WHAT: ABC² Brain Cancer ...
(Date:10/5/2017)... ... 2017 , ... Understanding the microbiome, the millions of bacteria that live in ... Are My Future, the newest exhibit on display at the University City Science Center’s ... through the lens of the gut microbiome. , Gut Love opens October 12, ...
Breaking Biology Technology:
(Date:3/24/2017)... The Controller General of Immigration from Maldives Mr. Mohamed Anwar ... prestigious international IAIR Award for the most innovative high security ePassport and ... ... Maldives Immigration Controller General, Mr. Mohamed ... the right) have received the IAIR award for the "Most innovative high ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
(Date:3/22/2017)... , March 21, 2017   Neurotechnology ... object recognition technologies, today announced the release of ... (SDK), which provides improved facial recognition using up ... on a single computer. The new version uses ... improve accuracy, and it utilizes a Graphing Processing ...
Breaking Biology News(10 mins):